ElevateBio Collaborates with AWS to Broaden the Potential of CRISPR Gene Editing Therapies with Generative AI
ElevateBio will leverage artificial intelligence to expand and accelerate CRISPR discovery, design, and drug development for thousands of complex monogenic and polygenic diseases
Generative AI combined with ElevateBio Life Edit's immense library of CRISPR systems and proprietary data from experiments will drive the synthesis and optimization of novel CRISPR drugs for genetic diseases
WALTHAM, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- ElevateBio, a technology-driven company focused on powering the creation of life-transforming genetic medicines, announced a multi-year collaboration with Amazon Web Services (AWS) to accelerate the discovery and development of CRISPR gene editing therapeutics through generative artificial intelligence (AI). ElevateBio aims to broaden the range of diseases addressable by gene editing therapies by combining the gene editing technologies and large CRISPR dataset of ElevateBio Life Edit – the Company's gene editing and R&D technology business – with AWS's advanced computing capabilities.
Under the collaboration, Life Edit will leverage AWS's cloud infrastructure and SageMaker, which integrates machine learning and analytics, to train and execute its state-of-the-art protein language models (PLMs) at scale. This will enable Life Edit to rapidly analyze and interpret vast amounts of protein and proprietary experimental data to identify, design, and optimize new CRISPR systems more efficiently than traditional methods.
'Our collaboration with AWS marks a leap forward in our mission to make transformative genetic medicines a reality for patients around the world,' said David Hallal, Chairman & CEO of ElevateBio. 'The first wave of CRISPR therapies has focused on a small number of monogenic diseases caused by single-gene mutations. By bringing together AWS's powerful cloud computing and AI solutions with our CRISPR dataset, we are taking on the challenge of expanding CRISPR's application to thousands of more complex monogenic disorders as well as polygenic diseases, paving the way for potentially curative treatments across therapeutic areas.'
CRISPR gene editing enables precise modifications to DNA, offering new possibilities for treating genetic disorders. The Life Edit gene editing platform is available to make a broad spectrum of edits – including base editing and reverse transcriptase editing – for the development of ex vivo and in vivo therapies. This collaboration will expand efforts to optimize and generate custom CRISPR therapies for genetic disease, both for partners and for internal pipeline development, with a focus on two key areas:
CRISPR discovery and design: Life Edit is analyzing its immense library of CRISPR systems, one of the largest in the industry, as well as data generated through experiments, to accelerate the discovery and design of both naturally occurring and synthetic custom CRISPR systems. Through a proof-of-concept project that leveraged AWS's infrastructure – including GPUs (graphics processing units) on Amazon EC2, Amazon S3, and Amazon SageMaker AI Studio – to share and power PLM evaluations with reduced complexity, Life Edit has already demonstrated an expansion of its protein discovery capabilities while significantly decreasing costs.
Target optimization: Using a combination of PLM-driven active learning and Life Edit's screens for DNA binding, nuclease activity, base editing, reverse transcriptase editing, and off-target activity, Life Edit is performing targeted protein optimization to design the best CRISPR proteins and improve their therapeutic potential.
'AWS is working with the team at ElevateBio to advance the field of CRISPR gene editing and bring the promise of personalized medicine closer to reality,' said Eric Zimmerman, Principal, Healthcare & Life Sciences Business Development, at AWS. 'By using AWS as the infrastructure for their CRISPR platform and to power their generative AI work, ElevateBio is combining in silico research with in vitro and in vivo data in the pursuit of developing life-saving therapies for patients.'
By integrating cutting-edge technology with deep scientific knowledge, ElevateBio Life Edit is dedicated to transforming the field of gene editing and unlocking the technology's full potential to provide life-changing treatments to patients in need.
About ElevateBio
ElevateBio is a technology-driven company built to power transformative genetic medicines today and for many decades to come. The Company commercializes its enabling technologies, manufacturing capabilities, and industry-leading expertise through partnerships to accelerate development across a breadth of therapeutic approaches and modalities. The ElevateBio ecosystem combines Life Edit, its gene editing and R&D technology business – which includes a full-spectrum gene editing platform; cell and RNA engineering technologies; and a viral and non-viral therapeutic delivery platform – with BaseCamp®, its end-to-end genetic medicine cGMP manufacturing and process development business, to accelerate the discovery and development of advanced therapeutics.
ElevateBio aims to be the dominant engine inside the world's greatest scientific advancements harnessing human cells and genes to alter disease. For more, visit www.elevate.bio or follow ElevateBio on LinkedIn or X.
Investor contact:
Catherine Hu
Media contact:
DJ Webster
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts
These biotech companies have several catalysts ahead -- and in the past have soared on good news. They both offer innovative candidates that could result in game-changing treatments for patients. 10 stocks we like better than Viking Therapeutics › If you're looking to add growth to your portfolio, biotech stocks can be a great choice. Exciting research is happening in these companies' labs, and in some cases, game-changing treatment candidates are approaching important milestones or even going over the finish line. As an investor in these companies, you can benefit as they report positive clinical trial news, score a regulatory approval, or start generating product revenue. Wall Street considers two candidates extremely compelling right now, with forecasts for potential gains of more than 80% and 200% in the coming 12 months. One of these players is working in the high-growth area of weight loss drugs, and the other candidate showed its strengths by winning the world's first-ever approval of a product based on CRISPR gene editing. Let's check out these two biotech stocks to buy before they skyrocket. Viking Therapeutics (NASDAQ: VKTX) soared early last year when it reported strong data from the phase 2 trial of its weight loss candidate, VK2735, but the stock has since given back those gains and is trading closer to the level it was at prior to that data announcement. Since, the company has continued to advance VK2735 in injectable form and a version in pill form, and demand for these sorts of drugs remains high -- these are two reasons to believe that Viking has the potential to take off again. And catalysts may be on the horizon. The drug works in a manner similar to Eli Lilly's blockbuster tirzepatide, sold under the names Mounjaro and Zepbound. These drugs interact with hormones involved in digestion and have helped people quickly and safely lose weight. Viking is beginning the phase 3 trial for injectable VK2735 in the second quarter and expects data from its phase 2 trial of the pill version in the second half. Any data announcements could result in big moves for the stock, as there is plenty of room for a new company to enter the weight loss drug market -- one forecast to approach $100 billion in a few years. Wall Street is optimistic about Viking's prospects, with the average price forecast predicting an increase of about 240% in the stock price from today's level. Of course, Viking depends heavily on the outcome of these trials, so some risk is involved -- but data have been strong, so growth investors may want to get in on Viking now to potentially post a big win later. CRISPR Therapeutics (NASDAQ: CRSP) stock surged in the year leading up to a major milestone: its first product approval. But since last year's launch of Casgevy, a gene-editing treatment for blood disorders, the stock has been on the decline. Sometimes, investors buy a stock well before the company wins approval or launches a product, then lock in gains after the good news lands -- and I think this is what's happened here. But what this does is offer us a chance to get in at a very good price on a promising company that could deliver fantastic news down the road. Casgevy, as a gene-editing treatment, requires a longer time to roll out than a pill or injection, as it includes several steps that happen over a period of months. The company recently said new patient initiations should increase "significantly" this year -- so there's reason to be optimistic about revenue growth ahead. CRISPR Therapeutics also recently reported positive phase 1 data for a gene editing candidate addressing the problem of high cholesterol. And the company expects to report data soon from a phase 1 trial of a candidate targeting patients with elevated levels of lipoprotein(a) -- a risk factor for cardiovascular events. These could represent huge markets for CRISPR Therapeutics if the candidates reach the finish line, and in the meantime, any potential positive news could boost the stock. The company also expects other trial updates in candidates for oncology and autoimmune diseases this year -- so this biotech's calendar is full of possible catalysts. Wall Street's average price forecast calls for an 84% gain for CRISPR Therapeutics from today's price -- if all goes well in clinical trials and Casgevy starts to show revenue growth, now could represent a golden buying opportunity for growth investors. Before you buy stock in Viking Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $664,089!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $881,731!* Now, it's worth noting Stock Advisor's total average return is 994% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends CRISPR Therapeutics. The Motley Fool recommends Viking Therapeutics. The Motley Fool has a disclosure policy. 2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts was originally published by The Motley Fool
Yahoo
5 hours ago
- Yahoo
2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts
These biotech companies have several catalysts ahead -- and in the past have soared on good news. They both offer innovative candidates that could result in game-changing treatments for patients. 10 stocks we like better than Viking Therapeutics › If you're looking to add growth to your portfolio, biotech stocks can be a great choice. Exciting research is happening in these companies' labs, and in some cases, game-changing treatment candidates are approaching important milestones or even going over the finish line. As an investor in these companies, you can benefit as they report positive clinical trial news, score a regulatory approval, or start generating product revenue. Wall Street considers two candidates extremely compelling right now, with forecasts for potential gains of more than 80% and 200% in the coming 12 months. One of these players is working in the high-growth area of weight loss drugs, and the other candidate showed its strengths by winning the world's first-ever approval of a product based on CRISPR gene editing. Let's check out these two biotech stocks to buy before they skyrocket. Viking Therapeutics (NASDAQ: VKTX) soared early last year when it reported strong data from the phase 2 trial of its weight loss candidate, VK2735, but the stock has since given back those gains and is trading closer to the level it was at prior to that data announcement. Since, the company has continued to advance VK2735 in injectable form and a version in pill form, and demand for these sorts of drugs remains high -- these are two reasons to believe that Viking has the potential to take off again. And catalysts may be on the horizon. The drug works in a manner similar to Eli Lilly's blockbuster tirzepatide, sold under the names Mounjaro and Zepbound. These drugs interact with hormones involved in digestion and have helped people quickly and safely lose weight. Viking is beginning the phase 3 trial for injectable VK2735 in the second quarter and expects data from its phase 2 trial of the pill version in the second half. Any data announcements could result in big moves for the stock, as there is plenty of room for a new company to enter the weight loss drug market -- one forecast to approach $100 billion in a few years. Wall Street is optimistic about Viking's prospects, with the average price forecast predicting an increase of about 240% in the stock price from today's level. Of course, Viking depends heavily on the outcome of these trials, so some risk is involved -- but data have been strong, so growth investors may want to get in on Viking now to potentially post a big win later. CRISPR Therapeutics (NASDAQ: CRSP) stock surged in the year leading up to a major milestone: its first product approval. But since last year's launch of Casgevy, a gene-editing treatment for blood disorders, the stock has been on the decline. Sometimes, investors buy a stock well before the company wins approval or launches a product, then lock in gains after the good news lands -- and I think this is what's happened here. But what this does is offer us a chance to get in at a very good price on a promising company that could deliver fantastic news down the road. Casgevy, as a gene-editing treatment, requires a longer time to roll out than a pill or injection, as it includes several steps that happen over a period of months. The company recently said new patient initiations should increase "significantly" this year -- so there's reason to be optimistic about revenue growth ahead. CRISPR Therapeutics also recently reported positive phase 1 data for a gene editing candidate addressing the problem of high cholesterol. And the company expects to report data soon from a phase 1 trial of a candidate targeting patients with elevated levels of lipoprotein(a) -- a risk factor for cardiovascular events. These could represent huge markets for CRISPR Therapeutics if the candidates reach the finish line, and in the meantime, any potential positive news could boost the stock. The company also expects other trial updates in candidates for oncology and autoimmune diseases this year -- so this biotech's calendar is full of possible catalysts. Wall Street's average price forecast calls for an 84% gain for CRISPR Therapeutics from today's price -- if all goes well in clinical trials and Casgevy starts to show revenue growth, now could represent a golden buying opportunity for growth investors. Before you buy stock in Viking Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $664,089!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $881,731!* Now, it's worth noting Stock Advisor's total average return is 994% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends CRISPR Therapeutics. The Motley Fool recommends Viking Therapeutics. The Motley Fool has a disclosure policy. 2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15 hours ago
- Yahoo
SentinelOne (S) Expands AI Cybersecurity Offerings on AWS
SentinelOne, Inc. (NYSE:S) is one of the . On June 16, the company announced that its AI-powered Security Information and Event Management (SIEM) solution– Singularity™ AI SIEM–is now available on the AWS Marketplace. Through the availability, AWS customers can now benefit from SentinelOne's AI and data capabilities to rapidly detect and respond to cyber threats across all attack surfaces. The AI SIEM is the latest SentinelOne offering to be made available on the marketplace, along with its flagship endpoint detection and response (EDR) offering and cloud security portfolio. Den Rise/ Sentinel One continues to solidify its strategic partnership with AWS, as reflected by a 100% year-over-year sales growth on AWS Marketplace. Its participation in AWS's Vendor Insights program allows it to enhance its appeal to customers who are already using AWS's services. 'Businesses are looking for faster and smarter ways to defend a rapidly growing attack surface against increasingly sophisticated adversaries. By bringing Singularity AI SIEM to the AWS Marketplace, we're making it far easier for more SecOps teams to harness the power of AI, automation and cloud-native data platforms to modernize the SOC and stop today's increasingly sophisticated threats.' -Ric Smith, President of Product, Technology, and Operations, SentinelOne. SentinelOne, Inc. (NYSE:S) is a provider of AI-powered cybersecurity solutions. While we acknowledge the potential of S as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Sign in to access your portfolio
